Pegadria 50mg Injection

Pegadria 50mg Injection is an anticancer medicine containing doxorubicin enclosed within a lipid vesicle (liposome). Cancer develops when cells multiply abnormally and without control. This medicine is used to treat breast cancer, ovarian cancer, multiple myeloma (cancer of plasma cells, a type of white blood cell), and AIDS-related Kaposi's sarcoma. Patients with HIV infection face the highest risk of developing Kaposi's sarcoma, a cancer that arises in the lining of lymph and blood vessels. Pegadria 50mg Injection may be administered as monotherapy or combined with other anticancer medicines. This medicine is not recommended for children and adolescents. Effective contraception should be used during treatment and for at least six months following the final dose. Before receiving Pegadria 50mg Injection, inform your doctor if you have allergies to peanuts or soya, if you are taking medicines for cardiac or hepatic disorders, if you have diabetes, Kaposi's sarcoma, or if you have oral complications.

Breast cancer Ovarian cancer Multiple myeloma AIDS-related Kaposi’s sarcoma

Pegadria 50mg Injection is a new class of drug formulations delivered in vesicles called liposomes. The mechanism of action of doxorubicin HCl is related to its ability to bind DNA and inhibit nucleic acid synthesis. Studies have demonstrated that the drug penetrates rapidly into the cell, binds to certain proteins in DNA, and thereby inhibits cell division and nucleic acid synthesis.

The drug should be administered only by physicians experienced with cancer chemotherapy. Your physician will determine the dose and frequency of administration based on the type of cancer and severity of the disease. Generally, for breast and ovarian cancer, the medicine is administered intravenously at a dose of 50 mg/m2 body surface once every 4 weeks for at least 4 courses. For treating AIDS-Kaposi Sarcoma, the drug is administered intravenously at a dose of 20 mg/m2 body surface once every two- to- three weeks only after the failure of prior systemic chemotherapy or intolerance to such therapy. For treating multiple myeloma, first bortezomib is administered at a dose of 1.3 mg/m2 as intravenous bolus on days 1, 4 , 8 and 11, every three weeks, then pegylated liposomal doxorubicin 30 mg/m2 should be administered as a 1-hr intravenous infusion on day 4 following bortezomib.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Serious Fever, tiredness, bruising or bleeding Severe diarrhea, sores in mouth, nausea, vomiting Lung infections, shortness of breath Severe stomach pain Severe weakness Common Low blood cell counts Hair loss Decreased appetite Skin rashes Pain in the muscles and joints Constipation Feeling confused, difficulty sleeping Headache, dizziness, sleepiness Change in taste High or low blood pressure Excessive sweating Pain when passing urine Weight loss Muscle spasms Fast heartbeat

Avoid prolonged sun exposure and unnecessary heat exposure (such as hot dishwater and long hot baths). Avoid pressure on elbows, knees, and soles of feet (such as leaning on elbows, kneeling, and long walks). Wear loose clothing. Keep this medicine out of sight and reach of children. Store the tablets at room temperature. Avoid keeping the tablet in direct sunlight or excessive moisture. This drug may cause dizziness. If you are affected by this side effect, do not drive, use machinery, or do anything that needs alert until you can do it safely.